Raymond Debbane Portfolio
Invests via Siren, L.L.C. | Managed by Raymond Debbane
Invests via Siren, L.L.C.
Managed by Raymond Debbane
Automatically Tracked
Raymond Debbane Profile
Seasoned technology and fintech investor and operator, Raymond Debbane is focused on growth-stage software, payments and digital services. He combines operating experience leading cross-functional teams with investment-oriented portfolio construction, active board involvement, and strategic M&A support to drive scaling and exit value. Investment style emphasizes product-market fit, unit economics, and repeatable revenue models. Background blends technical and commercial disciplines and a track record of partnering with founders to professionalize operations and drive capital-efficient growth.
Seasoned technology and fintech investor and operator, Raymond Debbane is focused on growth-stage software, payments and digital services. He combines operating experience leading cross-functional teams with investment-oriented portfolio construction, active board involvement, and strategic M&A support to drive scaling and exit value. Investment style emphasizes product-market fit, unit economics, and repeatable revenue models. Background blends technical and commercial disciplines and a track record of partnering with founders to professionalize operations and drive capital-efficient growth.
Investment Philosophy & Strategy
Focuses on growth-stage software, payments and digital services with a bias toward businesses demonstrating clear product-market fit, repeatable revenue and strong unit economics. Allocates capital to companies where operational improvements and go-to-market rigor can materially accelerate scale; prefers active minority or board-backed positions to influence strategy, metrics and M&A timing. Investment horizon targets multi-year value creation through capital-efficient growth, disciplined downside protection, founder partnership and pragmatic exit planning.
Focuses on growth-stage software, payments and digital services with a bias toward businesses demonstrating clear product-market fit, repeatable revenue and strong unit economics. Allocates capital to companies where operational improvements and go-to-market rigor can materially accelerate scale; prefers active minority or board-backed positions to influence strategy, metrics and M&A timing. Investment horizon targets multi-year value creation through capital-efficient growth, disciplined downside protection, founder partnership and pragmatic exit planning.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
129.07%
Gain -6.18%
Monthly
3.61%
Yearly
53.03%
Drawdown
43.78%
$4.53B
Equity
Holdings
$4.53B
Investment
$2.91B
$1.89B
Profit -$184.8M
Realized
$261.78M
Unrealized
$1.62B
Dividends
$875,357.71
Goals
Avg. 44.5% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
-6.18%
Profit
-$184.8M
Win %
65%
This Week
Compared To Last Week
Gain
-5.44%
Profit
-$260.65M
Win %
65%
This Month
Compared to last month
Gain
-3.96%
Profit
-$186.81M
Win %
65%
This Year
Compared to last year
Gain
-2.2%
Profit
-$102.72M
Win %
63%
MNDY monday.com Ltd.
+9.7%
+$354,450 
TSLA Tesla, Inc.
+3.8%
+$43,574.96 
GOOGL Alphabet Inc
+0.82%
+$253,799.1 
ABSI Absci Corporation
0%
$0 
AGEN Agenus Inc.
0%
$0 
AMLX Amylyx Pharmaceuticals, Inc. Common Stock
0%
$0 
AMZN Amazon.com Inc
0%
$0 
ANNX Annexon, Inc.
0%
$0 
ARWR Arrowhead Pharmaceuticals Inc.
0%
$0 
AVGO Broadcom Inc.
0%
+$0.3 
BABA Alibaba Group Holding Limited SP ADR
0%
$0 
BEKE Ke Holdings Inc. ADR
0%
$0 
BEIGF BeiGene Ltd.
0%
$0 
CGEM Cullinan Therapeutics, Inc.
0%
$0 
CLBT Cellebrite DI Ltd.
0%
$0 
COF Capital One Financial Corporation
0%
$0 
COGT Cogent Biosciences, Inc.
0%
$0 
CRNX Crinetics Pharmaceuticals Inc.
0%
$0 
CRWD CrowdStrike Holdings, Inc.
0%
$0 
CTMX CytomX Therapeutics Inc.
0%
$0 
CYTK Cytokinetics, Incorporated
0%
$0 
DBVT Dbv Technologies S.A. Sponsored ADR
0%
$0 
DDOG Datadog, Inc. Class A Common Stock
0%
$0 
DNLI Denali Therapeutics Inc.
0%
$0 
DT Dynatrace, Inc.
0%
$0 
DSGN Design Therapeutics, Inc.
0%
$0 
DYN Dyne Therapeutics Inc.
0%
$0 
ELVN Enliven Therapeutics, Inc.
0%
$0 
ENTX Entera Bio Ltd.
0%
$0 
ERAS Erasca, Inc.
0%
$0 
EWTX Edgewise Therapeutics, Inc.
0%
$0 
FHTX Foghorn Therapeutics Inc.
0%
$0 
FOXA Fox Corporation
0%
$0 
FROG JFrog Ltd
0%
$0 
GTLB GitLab Inc.
0%
$0 
IKT Inhibikase Therapeutics Inc.
0%
$0 
IONQ IonQ, Inc.
0%
$0 
IRON Disc Medicine Inc.
0%
$0 
IREN IREN Limited
0%
$0 
IVVD Invivyd Inc.
0%
+$0.05 
KYMR Kymera Therapeutics Inc.
0%
+$2.94 
LITE Lumentum Holdings Inc.
0%
+$0.03 
LXRX Lexicon Pharmaceuticals, Inc.
0%
$0 
MSFT Microsoft Corp.
0%
+$0.37 
NFLX Netflix, Inc.
0%
$0 
NMRA Neumora Therapeutics, Inc.
0%
$0 
NOW ServiceNow, Inc.
0%
$0 
NU Nu Holdings Ltd.
0%
$0 
NVDA NVIDIA Corporation
0%
$0 
OLMA Olema Pharmaceuticals Inc.
0%
$0 
ORIC Oric Pharmaceuticals Inc.
0%
$0 
OUST Ouster, Inc.
0%
$0 
PALI Palisade Bio Inc.
0%
$0 
RANI Rani Therapeutics Holdings Inc.
0%
+$0.06 
RCUS Arcus Biosciences Inc.
0%
$0 
RELY Remitly Global, Inc.
0%
$0 
RLAY Relay Therapeutics Inc.
0%
$0 
RYTM Rhythm Pharmaceuticals Inc.
0%
$0 
RZLT Rezolute, Inc.
0%
$0 
SEER Seer, Inc.
0%
$0 
SLDB Solid Biosciences Inc.
0%
$0 
SRRK Scholar Rock Holding Corporation
0%
$0 
STOK Stoke Therapeutics Inc.
0%
$0 
T AT&T Inc.
0%
$0 
TBLA Taboola.com Ltd.
0%
$0 
TENX Tenax Therapeutics Inc.
0%
$0 
TNGX Tango Therapeutics Inc.
0%
$0 
TRVI Trevi Therapeutics Inc.
0%
$0 
TSMWF Taiwan Semiconductor Manufacturing Company Limited
0%
$0 
TSHA Taysha Gene Therapies Inc.
0%
$0 
TYRA Tyra Biosciences, Inc.
0%
$0 
VTVT vTv Therapeutics Inc.
0%
$0 
WK Workiva Inc.
0%
$0 
XENE Xenon Pharmaceuticals Inc.
0%
$0 
ZTS Zoetis Inc.
0%
$0 
ZURA Zura Bio Ltd.
0%
$0 
FIG Figma Inc. Class A Common Stock
0%
$0 
ENGN enGene Therapeutics Inc.
0%
$0 
SYRE Spyre Therapeutics, Inc.
0%
+$3.87 
KRRO Korro Bio Inc.
0%
$0 
GPCR Structure Therapeutics Inc.
0%
$0 
RAPP Rapport Therapeutics Inc.
0%
$0 
NBIS Nebius Group N.V.
0%
$0 
ORKA Oruka Therapeutics, Inc.
0%
$0 
BCAX Bicara Therapeutics Inc.
0%
$0 
SEPN Septarna Inc.
0%
$0 
PVLA Pavella Therapeutics Inc.
0%
-$1.8 
SION Sionna Therapeutics Inc.
0%
$0 
KLRS Kalaris Therapeutics, Inc.
0%
$0 
WHWK Whitehawk Therapeutics, Inc.
0%
$0 
NBP NovaBridge Biosciences American Depositary Shares
0%
$0 
MPLT MapLight Therapeutics, Inc.
0%
$0 
MDLN Medline Inc.
0%
$0 
DFTX Definium Therapeutics, Inc.
0%
$0 
AGMB Agomab Therapeutics NV
0%
$0 
MANE Veradermics Inc.
0%
-$4.97 
GENB Generate Biomedicines, Inc.
0%
$0 OCS
OCS
0%
$0 
DMRA Damora Therapeutics, Inc.
0%
$0 
KLRA Kailera Therapeutics, Inc.
0%
$0 
SPTX Seaport Therapeutics, Inc.
0%
$0 
COAG Hemab Therapeutics Holdings, Inc.
0%
$0 
QNT Quantinuum Inc.
0%
$0 
PBLS Parabilis Medicines, Inc.
0%
$0 
SLNCF Silence Therapeutics plc
-26.54%
-$5.27M 
AEVA Aeva Technologies, Inc.
-10.89%
-$398,557.66 
ODTX Odyssey Therapeutics, Inc.
-3.98%
-$172,000 
MNPR Monopar Therapeutics Inc.
-3.91%
-$1.21M 
ABVX Abivax SA ADR
-3.24%
-$2.34M 
MSLE Satellos Bioscience Inc.
-2%
-$178,414.8 
RVMD Revolution Medicines Inc.
-1.59%
-$2.93M 
ADAG Adagene Inc.
-0.8%
-$79,999.98 
GOSS Gossamer Bio Inc.
-0.23%
-$2,083.59 
ELOX Eloxx Pharmaceuticals, Inc.
-0.03%
-$2,000 
PDD PDD Holdings Inc. American Depositary Shares
-0.01%
-$475.1 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 613 | Longs Won 331/613 53% | Profit Factor 3.65 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $20.09M |
| Average Win $7.85M | Best Trade (Sep 10) $395.28M | Sharpe Ratio -38.01 |
| Average Loss -$2.52M | Worst Trade (Sep 29) -$50.2M | Z-Score 1.05 (70.83%) |
| Commissions $0 | Avg. Trade Length 9m 2w 4d | Expectancy $3.08M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.07% |
| Consecutive Losing Trades | 1,795 | 1,616 | 1,436 | 1,257 | 1,077 | 898 | 718 | 539 | 359 | 180 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| ABSI Absci Corporation | 2.47M | $13.22M | $23.51M | - | $10.29M | 77.83% | 0.0 |
| ABVX Abivax SA ADR | 576,000 | $76.76M | $69.96M | - | -$6.8M | -8.86% | -3.243% |
| ADAG Adagene Inc. | 2.67M | $11.2M | $9.92M | - | -$1.28M | -11.43% | -0.8% |
| AEVA Aeva Technologies, Inc. | 145,459 | $2.47M | $3.26M | - | $795,208.42 | 32.25% | -10.89% |
| AGEN Agenus Inc. | 1.06M | $3.33M | $7.34M | - | $4.01M | 120.45% | 0.0 |
| AGMB Agomab Therapeutics NV | 411,250 | $4.31M | $5.8M | - | $1.49M | 34.51% | 0.0 |
| AMLX Amylyx Pharmaceuticals, Inc. Common Stock | 1.48M | $21.6M | $34.57M | - | $12.97M | 60.07% | 0.0 |
| AMZN Amazon.com Inc | 32,500 | $6.26M | $8.69M | - | $2.43M | 38.79% | 0.0 |
| ANNX Annexon, Inc. | 4.46M | $24.79M | $23.76M | - | -$1.02M | -4.12% | 0.0 |
| ARWR Arrowhead Pharmaceuticals Inc. | 1.72M | $44.17M | $149.68M | - | $105.5M | 238.84% | 0.0 |
| AVGO Broadcom Inc. | 25,000 | $8.68M | $10.4M | - | $1.72M | 19.88% | 0.0 |
| BABA Alibaba Group Holding Limited SP ADR | 50,000 | $4.8M | $6.26M | - | $1.46M | 30.46% | 0.0 |
| BCAX Bicara Therapeutics Inc. | 5.6M | $106.28M | $138M | - | $31.72M | 29.85% | 0.0 |
| BEIGF BeiGene Ltd. | 465,000 | $7.15M | $10.2M | - | $3.06M | 42.78% | 0.0 |
| BEKE Ke Holdings Inc. ADR | 100,000 | $1.96M | $1.74M | - | -$220,700 | -11.24% | 0.0 |
| CGEM Cullinan Therapeutics, Inc. | 1.89M | $32.72M | $37.11M | - | $4.39M | 13.4% | 0.0 |
| CLBT Cellebrite DI Ltd. | 311,544 | $4.82M | $4.75M | - | -$73,150.16 | -1.52% | 0.0 |
| COAG Hemab Therapeutics Holdings, Inc. | 2.09M | $57.85M | $111.6M | - | $53.76M | 92.93% | 0.0 |
| COF Capital One Financial Corporation | 171,615 | $34.43M | $38.17M | - | $3.74M | 10.88% | 0.0 |
| COGT Cogent Biosciences, Inc. | 1.86M | $26.83M | $72.47M | - | $45.65M | 170.14% | 0.0 |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Raymond Debbane?
The largest contributions to the portfolio's profits come from the following stocks: Scholar Rock Holding Corporation - $126.15M, Centessa Pharmaceuticals plc American Depositary Receipt - $91.82M, Arrowhead Pharmaceuticals Inc - $53.45M, Revolution Medicines Inc - $41.2M, and Tango Therapeutics Inc - $32.92M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Igm Biosciences Inc - $51.35M, Lexicon Pharmaceuticals, Inc - $39.27M, Rezolute, Inc - $34.28M, Vaxcyte, Inc - $24.5M, and MoonLake Immunotherapeutics - $20.35M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Raymond Debbane's portfolio generate?
The portfolio generates substantial dividend income, with a total of $875,357.71 earned over time. The largest contributors to dividend income include Microsoft Corp - $175,446.8, Taiwan Semiconductor Manufacturing Company Limited - $151,395.65, Capital One Financial Corporation - $137,292, QUALCOMM Incorporated - $75,340, and Alphabet Inc - $67,950.18. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Raymond Debbane's monthly returns?
Raymond Debbane's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can Raymond Debbane's strategy be considered aggressive or moderate?
Raymond Debbane's strategy can be considered aggressive. The combination of high drawdowns, elevated volatility, and/or concentrated positions suggests a willingness to accept significant risk in pursuit of higher long-term returns. This approach is generally more suitable for users who are comfortable with large fluctuations in portfolio value.
Should beginners follow Raymond Debbane's strategy?
Raymond Debbane's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
